Xiaoli Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaoli Zhou has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ao Wen
Department of Emergency Medicine and Laboratory of Ethnopharmacology, Tissue-Orientated Property of Chinese Medicine Key Laboratory of Sichuan Province, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
1 shared publication - Chengyu Wan
Laboratory of Ethnopharmacology, Tissue-Orientated Property of Chinese Medicine Key Laboratory of Sichuan Province, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
1 shared publication Depin Li
Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School Nanjing University Nanjing China
1 shared publication- Fan Li
Laboratory of Ethnopharmacology, Tissue-Orientated Property of Chinese Medicine Key Laboratory of Sichuan Province, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China
1 shared publication - Guang Xin
Department of Emergency Medicine, Natural and Biomimetic Medicine Research Center, Tissue-Orientated Property of Chinese Medicine Key Laboratory of Sichuan Province, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610000, China
1 shared publication - Hui Yang
Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School Nanjing University Nanjing China
1 shared publication
Latest Publications
- Open Access
- 15 July 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (7) , e72107
Exploring the Distinct Regulatory Actions and Molecular Pathways of Coptisine Through Network Pharmacology: Insights Into Its Influence on Platelet Activation and Thrombus Development
To investigate the potential targets and underlying mechanisms of coptisine in regulating platelet activation and thrombosis by integrating an approach combining network pharmacology and experimental validation. An in vivo carotid artery thrombosis model induced by FeCl 3 ‐mediated endothelial injury was established in mice to evaluate the antithrombotic effects of coptisine. A combination of network pharmacology prediction and both in vivo and in vitro experimental validation was employed to elucidate the antithrombotic mechanisms of coptisine. Molecular docking simulations were performed using AutoDock Vina to assess the binding interactions between coptisine and its targets. The in vitro antiplatelet effects of coptisine were assessed using platelet aggregation assays induced by thrombin, ADP, and collagen, as well as a thrombin‐induced platelet activation model. Administration of coptisine significantly reduced thrombus formation in the mouse model of carotid artery thrombosis. Network pharmacology analysis identified four key genes—NFKB1, PTGS2, STAT1, and ACE—as potential core targets contributing to the antithrombotic effects of coptisine. Functional enrichment analysis further indicated the involvement of these targets in pathways relevant to thrombosis and inflammation. Molecular docking studies demonstrated strong binding affinities between coptisine and the identified targets. Both in vivo and in vitro studies confirmed that coptisine treatment markedly attenuated thrombin‐induced platelet activation, as evidenced by reduced platelet inflammation and decreased levels of platelet granule release. This study demonstrates that coptisine exerts significant protective effects against thrombosis‐related diseases through modulation of the NF‐κB and MAPK signaling pathways.
- 15 July 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (7) , e72107
Open AccessExploring the Distinct Regulatory Actions and Molecular Pathways of Coptisine Through Network Pharmacology: Insights Into Its Influence on Platelet Activation and Thrombus Development
To investigate the potential targets and underlying mechanisms of coptisine in regulating platelet activation and thrombosis by integrating an approach combining network pharmacology and experimental validation. An in vivo carotid artery thrombosis model induced by FeCl 3 ‐mediated endothelial injury was established in mice to evaluate the antithrombotic effects of coptisine. A combination of network pharmacology prediction and both in vivo and in vitro experimental validation was employed to elucidate the antithrombotic mechanisms of coptisine. Molecular docking simulations were performed using AutoDock Vina to assess the binding interactions between coptisine and its targets. The in vitro antiplatelet effects of coptisine were assessed using platelet aggregation assays induced by thrombin, ADP, and collagen, as well as a thrombin‐induced platelet activation model. Administration of coptisine significantly reduced thrombus formation in the mouse model of carotid artery thrombosis. Network pharmacology analysis identified four key genes—NFKB1, PTGS2, STAT1, and ACE—as potential core targets contributing to the antithrombotic effects of coptisine. Functional enrichment analysis further indicated the involvement of these targets in pathways relevant to thrombosis and inflammation. Molecular docking studies demonstrated strong binding affinities between coptisine and the identified targets. Both in vivo and in vitro studies confirmed that coptisine treatment markedly attenuated thrombin‐induced platelet activation, as evidenced by reduced platelet inflammation and decreased levels of platelet granule release. This study demonstrates that coptisine exerts significant protective effects against thrombosis‐related diseases through modulation of the NF‐κB and MAPK signaling pathways.
- Open Access
- 19 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 4168
NINJ1 Regulates Platelet Activation and PANoptosis in Septic Disseminated Intravascular Coagulation
Disseminated intravascular coagulation (DIC), which is closely related to platelet activation, is a key factor leading to high mortality in sepsis. The release of contents from plasma membrane rupture after platelet death further aggravates thrombosis. Nerve injury-induced protein 1 (NINJ1) is a cell membrane protein that mediates membrane disruption, a typical marker of cell death, through oligomerization. Nevertheless, whether NINJ1 is expressed in platelets and regulates the platelet function remains unclear. The aim of this study was to evaluate the expression of NINJ1 in human and murine platelets and elucidate the role of NINJ1 in platelets and septic DIC. In this study, NINJ1 blocking peptide (NINJ126–37) was used to verify the effect of NINJ1 on platelets in vitro and in vivo. Platelet αIIbβ3 and P-selectin were detected by flow cytometry. Platelet aggregation was measured by turbidimetry. Platelet adhesion, spreading and NINJ1 oligomerization were examined by immunofluorescence. Cecal perforation-induced sepsis and FeCl3-induced thrombosis models were used to evaluate the role of NINJ1 in platelet, thrombus and DIC in vivo. We found that inhibition of NINJ1 alleviates platelet activation in vitro. The oligomerization of NINJ1 is verified in membrane-broken platelets, which is regulated by the PANoptosis pathway. In vivo studies demonstrate that inhibition of NINJ1 effectively reduces platelet activation and membrane disruption, thus suppressing platelet-cascade reaction and leading to anti-thrombosis and anti-DIC in sepsis. These data demonstrate that NINJ1 is critical in platelet activation and plasma membrane disruption, and inhibition of NINJ1 effectively reduces platelet-dependent thrombosis and DIC in sepsis. This is the first study to reveal the key role of NINJ1 in platelet and its related disorders.
- 19 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 4168
Open AccessNINJ1 Regulates Platelet Activation and PANoptosis in Septic Disseminated Intravascular Coagulation
Disseminated intravascular coagulation (DIC), which is closely related to platelet activation, is a key factor leading to high mortality in sepsis. The release of contents from plasma membrane rupture after platelet death further aggravates thrombosis. Nerve injury-induced protein 1 (NINJ1) is a cell membrane protein that mediates membrane disruption, a typical marker of cell death, through oligomerization. Nevertheless, whether NINJ1 is expressed in platelets and regulates the platelet function remains unclear. The aim of this study was to evaluate the expression of NINJ1 in human and murine platelets and elucidate the role of NINJ1 in platelets and septic DIC. In this study, NINJ1 blocking peptide (NINJ126–37) was used to verify the effect of NINJ1 on platelets in vitro and in vivo. Platelet αIIbβ3 and P-selectin were detected by flow cytometry. Platelet aggregation was measured by turbidimetry. Platelet adhesion, spreading and NINJ1 oligomerization were examined by immunofluorescence. Cecal perforation-induced sepsis and FeCl3-induced thrombosis models were used to evaluate the role of NINJ1 in platelet, thrombus and DIC in vivo. We found that inhibition of NINJ1 alleviates platelet activation in vitro. The oligomerization of NINJ1 is verified in membrane-broken platelets, which is regulated by the PANoptosis pathway. In vivo studies demonstrate that inhibition of NINJ1 effectively reduces platelet activation and membrane disruption, thus suppressing platelet-cascade reaction and leading to anti-thrombosis and anti-DIC in sepsis. These data demonstrate that NINJ1 is critical in platelet activation and plasma membrane disruption, and inhibition of NINJ1 effectively reduces platelet-dependent thrombosis and DIC in sepsis. This is the first study to reveal the key role of NINJ1 in platelet and its related disorders.